{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T16:56:15Z","timestamp":1767372975084,"version":"build-2065373602"},"reference-count":251,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GSK Laboratories"},{"name":"Sociedad Espa\u00f1ola de Quimioterapia"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The clinical evolution of patients infected with the Severe Acute Respiratory Coronavirus type 2 (SARS-CoV-2) depends on the complex interplay between viral and host factors. The evolution to less aggressive but better-transmitted viral variants, and the presence of immune memory responses in a growing number of vaccinated and\/or virus-exposed individuals, has caused the pandemic to slowly wane in virulence. However, there are still patients with risk factors or comorbidities that put them at risk of poor outcomes in the event of having the coronavirus infectious disease 2019 (COVID-19). Among the different treatment options for patients with COVID-19, virus-targeted measures include antiviral drugs or monoclonal antibodies that may be provided in the early days of infection. The present expert consensus is based on a review of all the literature published between 1 July 2021 and 15 February 2022 that was carried out to establish the characteristics of patients, in terms of presence of risk factors or comorbidities, that may make them candidates for receiving any of the virus-targeted measures available in order to prevent a fatal outcome, such as severe disease or death. A total of 119 studies were included from the review of the literature and 159 were from the additional independent review carried out by the panelists a posteriori. Conditions found related to strong recommendation of the use of virus-targeted measures in the first days of COVID-19 were age above 80 years, or above 65 years with another risk factor; antineoplastic chemotherapy or active malignancy; HIV infection with CD4+ cell counts &lt; 200\/mm3; and treatment with anti-CD20 immunosuppressive drugs. There is also a strong recommendation against using the studied interventions in HIV-infected patients with a CD4+ nadir &lt;200\/mm3 or treatment with other immunosuppressants. Indications of therapies against SARS-CoV-2, regardless of vaccination status or history of infection, may still exist for some populations, even after COVID-19 has been declared to no longer be a global health emergency by the WHO.<\/jats:p>","DOI":"10.3390\/v15071449","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:25:21Z","timestamp":1687911921000},"page":"1449","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9840-6556","authenticated-orcid":false,"given":"Francisco Javier","family":"Candel","sequence":"first","affiliation":[{"name":"Clinical Microbiology & Infectious Diseases, Transplant Coordination, Hospital Cl\u00ednico Universitario San Carlos, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Barreiro","sequence":"additional","affiliation":[{"name":"Regional Public Health Laboratory, Infectious Diseases, Internal Medicine, Hospital General Universitario La Paz, 28055 Madrid, Spain"},{"name":"Department of Medical Specialities and Public Health, Universidad Rey Juan Carlos, 28922 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8571-2124","authenticated-orcid":false,"given":"Miguel","family":"Salavert","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Internal Medicine, Hospital Universitario y Polit\u00e9cnico La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8429-8358","authenticated-orcid":false,"given":"Alfonso","family":"Cabello","sequence":"additional","affiliation":[{"name":"Internal Medicine, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0315-8001","authenticated-orcid":false,"given":"Mario","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201c12 de Octubre\u201d, Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), 28041 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"P\u00e9rez-Segura","sequence":"additional","affiliation":[{"name":"Medical Oncology, Hospital Cl\u00ednico Universitario San Carlos, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4242-0436","authenticated-orcid":false,"given":"Jes\u00fas","family":"San Rom\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Medical Specialities and Public Health, Universidad Rey Juan Carlos, 28922 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8541-8200","authenticated-orcid":false,"given":"Juan","family":"Berenguer","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), 28007 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7654-8836","authenticated-orcid":false,"given":"Ra\u00fal","family":"C\u00f3rdoba","sequence":"additional","affiliation":[{"name":"Haematology and Haemotherapy, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-4736","authenticated-orcid":false,"given":"Rafael","family":"Delgado","sequence":"additional","affiliation":[{"name":"Clinical Microbiology, Hospital Universitario \u201c12 de Octubre\u201d, Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12), 28041 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Pablo","family":"Espa\u00f1a","sequence":"additional","affiliation":[{"name":"Pneumology, Hospital Universitario de Galdakao-Usansolo, 48960 Vizcaya, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio Alberto","family":"G\u00f3mez-Centuri\u00f3n","sequence":"additional","affiliation":[{"name":"Haematology and Haemotherapy, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, 28007 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Mar\u00eda","family":"Gonz\u00e1lez del Castillo","sequence":"additional","affiliation":[{"name":"Emergency Department, Hospital Cl\u00ednico Universitario San Carlos, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4901-6487","authenticated-orcid":false,"given":"Sarah B\u00e9atrice","family":"Heili","sequence":"additional","affiliation":[{"name":"Intermediate Respiratory Care Unit, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"Mart\u00ednez-Peromingo","sequence":"additional","affiliation":[{"name":"Department of Medical Specialities and Public Health, Universidad Rey Juan Carlos, 28922 Madrid, Spain"},{"name":"Geriatrics, Hospital Universitario Rey Juan Carlos, 28933 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Men\u00e9ndez","sequence":"additional","affiliation":[{"name":"Pneumology, Hospital Universitario y Polit\u00e9cnico La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2843-1094","authenticated-orcid":false,"given":"Santiago","family":"Moreno","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7229-6005","authenticated-orcid":false,"given":"Jos\u00e9 Lu\u00eds","family":"Pablos","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Universitario \u201c12 de Octubre\u201d, Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12), 28041 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Pasquau","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Pi\u00f1ana","sequence":"additional","affiliation":[{"name":"Haematology and Haemotherapy, Hospital Cl\u00ednico Universitario de Valencia, 46010 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the MODUS Investigators (Adenda)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"key":"ref_1","unstructured":"COVID-19 Map\u2014Johns Hopkins Coronavirus Resource Center (2020, September 05). Available online: https:\/\/coronavirus.jhu.edu\/map.html."},{"key":"ref_2","unstructured":"COVID-19 Situation Update for the EU\/EEA, as of 31 August 2022 (2020, September 05). European Centre for Disease Prevention and Control. Available online: https:\/\/www.ecdc.europa.eu\/en\/cases-2019-ncov-eueea."},{"key":"ref_3","unstructured":"Centro de Coodinaci\u00f3n de Alertas y Emergencias Sanitarias, Ministerio de Sanidad de Espa\u00f1a (2022, October 15). Actualizaci\u00f3n No 589. Enfermedad por el Coronavirus (COVID-19). Available online: https:\/\/www.sanidad.gob.es\/profesionales\/saludPublica\/ccayes\/alertasActual\/nCov\/documentos\/Actualizacion_589_COVID-19.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2022.2274","article-title":"Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada","volume":"327","author":"Ulloa","year":"2022","journal-title":"JAMA"},{"key":"ref_8","unstructured":"Arribas, J.R., Garcia-Vidal, C., Pa\u00f1o, J.R., and Ba\u00f1o, J.R. (2022, October 15). Available online: https:\/\/seimc.org\/contenidos\/documentoscientificos\/recomendaciones\/seimc-rc-2020-COVID19-manejoclinico.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.15585\/mmwr.mm7101a4","article-title":"Risk Factors for Severe COVID-19 Outcomes Among Persons Aged \u2265 18 Years Who Completed a Primary COVID-19 Vaccination Series\u2014465 Health Care Facilities, United States, December 2020\u2013October 2021","volume":"71","author":"Yek","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"m1966","DOI":"10.1136\/bmj.m1966","article-title":"Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study","volume":"369","author":"Petrilli","year":"2020","journal-title":"BMJ"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jamda.2020.05.045","article-title":"The Effect of Age on Mortality in Patients with COVID-19: A Meta-Analysis with 611,583 Subjects","volume":"21","author":"Bonanad","year":"2020","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/j.jinf.2020.04.021","article-title":"Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis","volume":"81","author":"Zheng","year":"2020","journal-title":"J. Infect."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.dsx.2020.06.064","article-title":"Coronavirus disease (COVID-19): A systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events","volume":"14","author":"Nandy","year":"2020","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ccell.2020.09.007","article-title":"SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19","volume":"38","author":"Westblade","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3026(20)30429-4","article-title":"Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: An observational cohort study","volume":"8","author":"Sharma","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00296-021-04969-2","article-title":"Protracted severe COVID-19 pneumonia following rituximab treatment: Caution needed","volume":"41","author":"Daoussis","year":"2021","journal-title":"Rheumatol. Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/BOR.0000000000000776","article-title":"COVID-19 and autoimmune diseases","volume":"33","author":"Liu","year":"2020","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/TP.0000000000003528","article-title":"Organ Donation and Transplantation During the COVID-19 Pandemic: A Summary of the Spanish Experience","volume":"105","author":"Crespo","year":"2021","journal-title":"Transplantation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"458","DOI":"10.15585\/mmwr.mm6915e3","article-title":"Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019\u2014COVID-NET, 14 States, March 1\u201330, 2020","volume":"69","author":"Garg","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.15585\/mmwr.mm6912e2","article-title":"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19)\u2014United States, February 12\u2013March 16, 2020","volume":"69","author":"Bialek","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00431-020-03684-7","article-title":"SARS-CoV-2 infection in children and newborns: A systematic review","volume":"179","author":"Liguoro","year":"2020","journal-title":"Eur. J. Pediatr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-4642(21)00066-3","article-title":"Children and young people remain at low risk of COVID-19 mortality","volume":"5","author":"Bhopal","year":"2021","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"21011","DOI":"10.1073\/pnas.2011086117","article-title":"Overweight, obesity, and risk of hospitalization for COVID-19: A community-based cohort study of adults in the United Kingdom","volume":"117","author":"Hamer","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"108374","DOI":"10.1016\/j.diabres.2020.108374","article-title":"Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration","volume":"168","author":"Fadini","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2337\/dc20-0723","article-title":"Outcomes in Patients with Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?","volume":"43","author":"Sardu","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S2213-2600(21)00095-3","article-title":"Association between pre-existing respiratory disease and its treatment, and severe COVID-19: A population cohort study","volume":"9","author":"Aveyard","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2004474","DOI":"10.1183\/13993003.04474-2020","article-title":"Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: A nationwide study","volume":"58","author":"Beltramo","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ssentongo, P., Ssentongo, A.E., Heilbrunn, E.S., Ba, D.M., and Chinchilli, V.M. (2020). Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0238215"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1212\/WNL.0000000000009673","article-title":"Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19","volume":"95","author":"Herman","year":"2020","journal-title":"Neurology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/ageing\/afab096","article-title":"The demography and characteristics of SARS-CoV-2 seropositive residents and staff of nursing homes for older adults in the Community of Madrid: The SeroSOS study","volume":"50","author":"Candel","year":"2021","journal-title":"Age Ageing"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jinf.2021.01.022","article-title":"COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients","volume":"82","author":"Belsky","year":"2021","journal-title":"J. Infect."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e1964","DOI":"10.1093\/cid\/ciaa1339","article-title":"Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients with Human Immunodeficiency Virus and Coronavirus Disease 2019","volume":"73","author":"Dandachi","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/j.clon.2020.11.006","article-title":"Clinical Characteristics and Outcomes in Patients with COVID-19 and Cancer: A Systematic Review and Meta-analysis","volume":"33","author":"Zarifkar","year":"2021","journal-title":"Clin. Oncol. (R Coll Radiol)"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"key":"ref_36","first-page":"n2244","article-title":"Risk prediction of COVID-19 related death and hospital admission in adults after COVID-19 vaccination: National prospective cohort study","volume":"374","author":"Coupland","year":"2021","journal-title":"BMJ"},{"key":"ref_37","unstructured":"Centres for Disease Control and Prevention (CDC) (2022, September 06). Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals, Available online: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-care\/underlyingconditions.html."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.5888\/pcd18.210123","article-title":"Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized with COVID-19, March 2020\u2013March 2021","volume":"18","author":"Kompaniyets","year":"2021","journal-title":"Prev. Chronic Dis."},{"key":"ref_39","first-page":"23","article-title":"Manejo de la Infecci\u00f3n por SARS-CoV-2 en Urgencias","volume":"1","author":"Losa","year":"2022","journal-title":"Rev. Espa\u00f1ola Urgenc. Emerg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/infdis\/jiab570","article-title":"Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities","volume":"225","author":"Bierle","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_41","unstructured":"(2022, September 06). SEIMC Score Mortality\u2014SEIMC\u2014COVID-19. Available online: https:\/\/covid19.seimc.org\/index.php\/seimc-score-mortalidad\/."},{"key":"ref_42","unstructured":"(2022, September 06). QCovidTM Risk Calculator. Available online: https:\/\/qcovid.org\/."},{"key":"ref_43","unstructured":"Shinyapps (2022, September 06). PrediCOVID-ED. Available online: https:\/\/predicovid.shinyapps.io\/RISK_MODEL_COVID\/."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"m3862","DOI":"10.1136\/bmj.m3862","article-title":"Virology, transmission, and pathogenesis of SARS-CoV-2","volume":"371","author":"Cevik","year":"2020","journal-title":"BMJ"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early Treatment for COVID-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early Remdesivir to Prevent Progression to Severe COVID-19 in Outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients","volume":"386","author":"Musungaie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1038\/s41467-022-31615-7","article-title":"Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains","volume":"13","author":"Case","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(22)01938-9","article-title":"WHO\u2019s Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed","volume":"400","author":"Wu","year":"2022","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e071932","DOI":"10.1136\/bmj-2022-071932","article-title":"Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe COVID-19 outcomes in non-hospitalised patients: An observational cohort study using the OpenSAFELY platform","volume":"379","author":"Zheng","year":"2022","journal-title":"BMJ"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/j.jinf.2022.06.033","article-title":"Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2","volume":"85","author":"Marcelin","year":"2022","journal-title":"J. Infect."},{"key":"ref_53","unstructured":"UK Health Security Agency (2022, October 18). SARS-CoV-2 Therapeutics Technical Briefing 3. Genomic Surveillance, Available online: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1074186\/therapeutics-programme-technical-briefing-3.pdf."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"100850","DOI":"10.1016\/j.xcrm.2022.100850","article-title":"Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 in patients receiving monoclonal antibodies","volume":"3","author":"Bruel","year":"2022","journal-title":"Cell. Rep. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"Barnes","year":"2020","journal-title":"Nature"},{"key":"ref_56","unstructured":"Stanford University (2022, September 06). Stanford Coronavirus Antiviral & Resistance Database (CoVDB). Available online: https:\/\/covdb.stanford.edu\/."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1654.e1\u20131654.e4","DOI":"10.1016\/j.cmi.2022.07.015","article-title":"Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients","volume":"28","author":"Nguyen","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S2213-2600(22)00180-1","article-title":"Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): A phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Montgomery","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"eabn9243","DOI":"10.1126\/scitranslmed.abn9243","article-title":"Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines","volume":"14","author":"Bartsch","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"100721","DOI":"10.1016\/j.xcrm.2022.100721","article-title":"Antibody therapy reverses biological signatures of COVID-19 progression","volume":"3","author":"Maher","year":"2022","journal-title":"Cell. Rep. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41579-022-00713-0","article-title":"SARS-CoV-2 pathogenesis","volume":"20","author":"Lamers","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of COVID-19\u2014Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed Antiviral Drugs for COVID-19\u2014Interim WHO Solidarity Trial Results","volume":"384","author":"Hongchao","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_65","first-page":"m2980.49","article-title":"Drug treatments for COVID-19: Living systematic review and network meta-analysis","volume":"370","author":"Siemieniuk","year":"2020","journal-title":"BMJ"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/jama.2022.0335","article-title":"COVID-19 Therapeutics for Nonhospitalized Patients","volume":"327","author":"Gandhi","year":"2022","journal-title":"JAMA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"m2924","DOI":"10.1136\/bmj.m2924","article-title":"Remdesivir for severe COVID-19: A clinical practice guideline","volume":"370","author":"Rochwerg","year":"2020","journal-title":"BMJ"},{"key":"ref_69","first-page":"CD014962","article-title":"Remdesivir for the treatment of COVID-19","volume":"8","author":"Grundeis","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1473-3099(21)00485-0","article-title":"Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): A phase 3, randomised, controlled, open-label trial","volume":"22","author":"Ader","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"701","DOI":"10.7326\/M21-4784","article-title":"Major Update 2: Remdesivir for Adults with COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points","volume":"175","author":"Kaka","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(22)00528-8","article-title":"Effects of remdesivir in patients hospitalised with COVID-19: A systematic review and individual patient data meta-analysis of randomised controlled trials","volume":"11","author":"Amstutz","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"E242","DOI":"10.1503\/cmaj.211698","article-title":"Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: A randomized controlled trial","volume":"194","author":"Ali","year":"2022","journal-title":"Can. Med. Assoc. J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1093\/cid\/ciab875","article-title":"Remdesivir Treatment in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort","volume":"75","author":"Mozaffari","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/cid\/ciac769","article-title":"Remdesivir Resistance in Transplant Recipients with Persistent Coronavirus Disease 2019","volume":"76","author":"Hogan","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients","volume":"76","author":"Gronich","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/cid\/ciac673","article-title":"Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients with Coronavirus Disease 2019","volume":"76","author":"Ganatra","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1001\/jama.2022.9925","article-title":"From Positive to Negative to Positive Again\u2014The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid","volume":"327","author":"Rubin","year":"2022","journal-title":"JAMA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): An open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler","year":"2023","journal-title":"Lancet"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0140-6736(22)01586-0","article-title":"Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: An observational study","volume":"400","author":"Wong","year":"2022","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1473-3099(22)00644-2","article-title":"Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): A randomised, placebo-controlled, double-blind, phase 2 trial","volume":"23","author":"Khoo","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s43440-022-00408-6","article-title":"Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance","volume":"74","author":"Flisiak","year":"2022","journal-title":"Pharmacol. Rep."},{"key":"ref_83","unstructured":"EMA (2023, April 21). Refusal of the Marketing Authorisation for Lagevrio (Molnupiravir). Available online: www.ema.europa.eu\/en\/documents\/smop-initial\/questions-answers-refusal-marketing-authorisation-lagevrio-molnupiravir_en.pdf."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"ofab453","DOI":"10.1093\/ofid\/ofab453","article-title":"Association between SARS-CoV-2 cycle threshold values and clinical outcomes in patients with COVID-19: A systematic review and meta-analysis","volume":"8","author":"Shah","year":"2021","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_85","first-page":"32","article-title":"Qualitative subgenomic RNA to monitor the response to remdesivir in hos-pitalized patients with COVID-19: Impact on the length of hospital stay and mortality","volume":"76","author":"Cuesta","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cmi.2021.08.009","article-title":"Diagnostic usefulness of subgenomic RNA detection of viable SARS-CoV-2 in patients with COVID-19","volume":"28","author":"Kim","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1093\/cid\/ciab154","article-title":"Characteristics and Factors Associated with Coronavirus Disease 2019 Infection, Hospitalization, and Mortality Across Race and Ethnicity","volume":"73","author":"Dai","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"100104","DOI":"10.1016\/j.lanepe.2021.100104","article-title":"Changes in COVID-19 in-hospital mortality in hospitalised adults in England over the first seven months of the pandemic: An observational study using administrative data","volume":"5","author":"Gray","year":"2021","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jiph.2021.03.016","article-title":"Prevalence and predictors of in-hospital mortality of patients hospitalized with COVID-19 infection","volume":"14","author":"Khamis","year":"2021","journal-title":"J. Infect. Public Health"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Castilla, J., Guevara, M., Miqueleiz, A., Baigorria, F., Ibero-Esparza, C., Navascu\u00e9s, A., Trobajo-Sanmart\u00edn, C., Mart\u00ednez-Baz, I., Casado, I., and Burgui, C. (2021). Risk Factors of Infection, Hospitalization and Death from SARS-CoV-2: A Population-Based Cohort Study. J. Clin. Med., 10.","DOI":"10.3390\/jcm10122608"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"673527","DOI":"10.3389\/frai.2021.673527","article-title":"Symptom Prediction and Mortality Risk Calculation for COVID-19 Using Machine Learning","volume":"4","author":"Jamshidi","year":"2021","journal-title":"Front. Artif. Intell."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S2213-2600(21)00380-5","article-title":"COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2\u00b757 million people in Scotland (EAVE II): A prospective cohort study","volume":"9","author":"Agrawal","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e00049821","DOI":"10.1590\/0102-311x00049821","article-title":"Identification of priority groups for COVID-19 vaccination in Brazil","volume":"37","author":"Lana","year":"2021","journal-title":"Cad Saude Publica"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/01410768211051715","article-title":"Association between multimorbidity and mortality in a cohort of patients admitted to hospital with COVID-19 in Scotland","volume":"115","author":"Agrawal","year":"2022","journal-title":"J. R. Soc. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e001002","DOI":"10.1136\/bmjresp-2021-001002","article-title":"Risk factors of mortality among patients hospitalised with COVID-19 in a critical care or hospital care unit: Analysis of the French national medico administrative database","volume":"8","author":"Ouattara","year":"2021","journal-title":"BMJ Open Respir. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/14760584.2022.2019582","article-title":"Predicting the risk of severe COVID-19 outcomes in primary care: Development and validation of a vulnerability index for equitable allocation of effective vaccines","volume":"21","author":"Lapi","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"ref_97","first-page":"100167","article-title":"Why should obese youth be prioritized in COVID-19 vaccination programs? A nationwide retrospective study","volume":"7","author":"Discacciati","year":"2022","journal-title":"Lancet Reg. Health Am."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Israel, A., Sch\u00e4ffer, A.A., Merzon, E., Green, I., Magen, E., Golan-Cohen, A., Vinker, S., and Ruppin, E. (2022). A calculator for COVID-19 severity prediction based on patient risk factors and number of vaccines received. Microorganisms, 10.","DOI":"10.3390\/microorganisms10061238"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/tmi.13752","article-title":"Western Cape and South African National Departments of Health in collaboration with the National Institute for Communicable Diseases in South Africa Affiliations. Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa","volume":"27","author":"Davies","year":"2022","journal-title":"Trop. Med. Int. Health"},{"key":"ref_100","first-page":"477","article-title":"Working Group TC. COPD in SARS-CoV-2 pandemic. baseline characteristics related to hospital admissions","volume":"16","author":"Esteban","year":"2022","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s11739-022-02931-z","article-title":"Modelling the risk of hospital admission of lab confirmed SARS-CoV-2-infected patients in primary care: A population-based study","volume":"17","year":"2022","journal-title":"Intern. Emerg. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijid.2022.02.007","article-title":"Hospitalized patients with breakthrough COVID-19: Clinical features and poor outcome predictors","volume":"118","author":"Ribes","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"603","DOI":"10.12788\/jhm.3689","article-title":"Factors Associated with COVID-19 Disease Severity in US Children and Adolescents","volume":"16","author":"Antoon","year":"2021","journal-title":"J. Hosp. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"101287","DOI":"10.1016\/j.eclinm.2022.101287","article-title":"Which children and young people are at higher risk of severe disease and death after hospitalisation with SARS-CoV-2 infection in children and young people: A systematic review and individual patient meta-analysis","volume":"44","author":"Harwood","year":"2022","journal-title":"Eclinicalmedicine"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"18474","DOI":"10.1038\/s41598-021-98008-6","article-title":"Modelling COVID-19 severity in the Republic of Ireland using patient co-morbidities, socioeconomic profile and geographic location, February to November 2020","volume":"11","author":"Boudou","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Ge, E., Li, Y., Wu, S., Candido, E., and Wei, X. (2021). Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0258154"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(22)01656-7","article-title":"Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: Pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales","volume":"400","author":"Agrawal","year":"2022","journal-title":"Lancet"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"100158","DOI":"10.1016\/j.lanepe.2021.100158","article-title":"Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: A cohort study of 66 million people","volume":"8","author":"Semenzato","year":"2021","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/oby.23178","article-title":"Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVID-19: Analysis of the ISARIC CCP-UK Cohort","volume":"29","author":"Yates","year":"2021","journal-title":"Obesity (Silver Spring)"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Treskova-Schwarzbach, M., Haas, L., Reda, S., Pilic, A., Borodova, A., Karimi, K., Koch, J., Nygren, T., Scholz, S., and Sch\u00f6nfeld, V. (2021). Pre-existing health conditions and severe COVID-19 outcomes: An umbrella review approach and meta-analysis of global evidence. BMC Med., 19.","DOI":"10.1186\/s12916-021-02058-6"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3390\/idr13030065","article-title":"Unusually High Risks of COVID-19 Mortality with Age-Related Comorbidities: An Adjusted Meta-Analysis Method to Improve the Risk Assessment of Mortality Using the Comorbid Mortality Data","volume":"13","author":"Antos","year":"2021","journal-title":"Infect. Dis. Rep."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000524553","article-title":"Cross-Sectional Analysis of Risk Factors for Outbreak of COVID-19 in Nursing Homes for Older Adults in the Community of Madrid","volume":"69","author":"Candel","year":"2023","journal-title":"Gerontology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"104324","DOI":"10.1016\/j.archger.2020.104324","article-title":"Clinical frailty scale and mortality in COVID-19: A systematic review and dose-response meta-analysis","volume":"93","author":"Pranata","year":"2021","journal-title":"Arch. Gerontol. Geriatr."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.recesp.2018.06.015","article-title":"Recomendaciones de la Secci\u00f3n de Cardiolog\u00eda Geri\u00e1trica de la Sociedad Espa\u00f1ola de Cardiolog\u00eda para la valoraci\u00f3n de la fragilidad en el anciano con cardiopat\u00eda","volume":"72","author":"Bonanad","year":"2019","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e775","DOI":"10.1097\/TXD.0000000000001234","article-title":"COVID-19 in Solid Organ Transplantation: Results of the National COVID Cohort Collaborative","volume":"7","author":"Vinson","year":"2021","journal-title":"Transplant. Direct"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1097\/TP.0000000000003873","article-title":"COVID-19 in Solid Organ Transplant Recipients in Spain Throughout 2020: Catching the Wave?","volume":"105","author":"Coll","year":"2021","journal-title":"Transplantation"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"100628","DOI":"10.1016\/j.trre.2021.100628","article-title":"The association between severe or death COVID-19 and solid organ transplantation: A systematic review and meta-analysis","volume":"35","author":"Ao","year":"2021","journal-title":"Transplant. Rev. (Orlando)"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Linares, L., Cofan, F., Diekmann, F., Herrera, S., Marcos, M.A., Castel, M.A., Farrero, M., Colmenero, J., Ruiz, P., and Crespo, G. (2021). A propensity score-matched analysis of mortality in solid organ transplant patients with COVID-19 compared to non-solid organ transplant patients. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0247251"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e4090","DOI":"10.1093\/cid\/ciaa1097","article-title":"Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study","volume":"73","author":"Kates","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/nep.13974","article-title":"Humoral and cellular immune response to severe acute respiratory syndrome coronavirus-2 vaccination in haemodialysis and kidney transplant patients","volume":"27","author":"Swai","year":"2022","journal-title":"Nephrology (Carlton)"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"832501","DOI":"10.3389\/fimmu.2022.832501","article-title":"Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls","volume":"13","author":"Hamm","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/TP.0000000000004059","article-title":"Real-world Effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S Vaccines Against SARS-CoV-2 in Solid Organ and Islet Transplant Recipients","volume":"106","author":"Callaghan","year":"2022","journal-title":"Transplantation"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e13779","DOI":"10.1111\/tid.13779","article-title":"Breakthrough COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy","volume":"24","author":"Yetmar","year":"2022","journal-title":"Transpl. Infect. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"E265","DOI":"10.1097\/TP.0000000000003907","article-title":"Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients","volume":"105","author":"Qin","year":"2021","journal-title":"Transplantation"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1097\/TP.0000000000004150","article-title":"Sotrovimab in Solid Organ Transplant Patients with Early, Mild\/Moderate SARS-CoV-2 Infection: A Single-center Experience","volume":"106","author":"Pinchera","year":"2022","journal-title":"Transplantation"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/ajt.16843","article-title":"Use of anti-spike monoclonal antibodies in kidney transplant recipients with COVID-19: Efficacy, ethnic and racial disparities","volume":"22","author":"Klein","year":"2022","journal-title":"Am. J. Transplant."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.kint.2022.04.003","article-title":"Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection","volume":"101","author":"Chavarot","year":"2022","journal-title":"Kidney Int."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/TP.0000000000003744","article-title":"Evidence of SARS-CoV-2 Infection in Cells, Tissues, and Organs and the Risk of Transmission Through Transplantation","volume":"105","author":"Gaussen","year":"2021","journal-title":"Transplantation"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e13503","DOI":"10.1111\/tid.13503","article-title":"Organ recovery from deceased donors with prior COVID-19: A case series","volume":"23","author":"Neidlinger","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1111\/ajt.16823","article-title":"Liver transplantation from active COVID-19 donors: A lifesaving opportunity worth grasping?","volume":"21","author":"Romagnoli","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e13707","DOI":"10.1111\/tid.13707","article-title":"Successful heart and kidney transplantation from a deceased donor with PCR positive COVID-19","volume":"23","author":"Sigler","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1111\/ajt.16765","article-title":"Early success transplanting kidneys from donors with new SARS-CoV-2 RNA positivity: A report of 10 cases","volume":"21","author":"Koval","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e13761","DOI":"10.1111\/tid.13761","article-title":"Solid non-lung organs from COVID-19 donors in seropositive or naive recipients: Where do we stand?","volume":"24","author":"Saracco","year":"2022","journal-title":"Transpl. Infect. Dis."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1111\/ajt.16706","article-title":"Successful transplantation of organs from a deceased donor with early SARS-CoV-2 infection","volume":"21","author":"Dhand","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e13727","DOI":"10.1111\/tid.13727","article-title":"The pandemic provides a pathway: What we know and what we need to know about using COVID positive donors","volume":"23","author":"Eichenberger","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1111\/ajt.16532","article-title":"Donor to recipient transmission of SARS-CoV-2 by lung transplantation despite negative donor upper respiratory tract testing","volume":"21","author":"Kaul","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1111\/ajt.16576","article-title":"A call to routinely test lower respiratory tract samples for SARS-CoV-2 in lung donors","volume":"21","author":"Kumar","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1172\/JCI141777","article-title":"Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation","volume":"130","author":"Shah","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1038\/s41409-021-01278-x","article-title":"COVID-19 in recipients of allogeneic stem cell transplantation: Favorable outcome","volume":"56","author":"Xue","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e13625","DOI":"10.1111\/tid.13625","article-title":"Clinical presentation and outcomes of COVID-19 following hematopoietic cell transplantation and cellular therapy","volume":"23","author":"Camargo","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1038\/s41375-021-01302-5","article-title":"COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey","volume":"35","author":"Ljungman","year":"2021","journal-title":"Leukemia"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/bjh.17280","article-title":"The NICE COVID-19 rapid guideline on haematopoietic stem cell transplantation: Development, implementation and impact","volume":"192","author":"Orchard","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1038\/s41409-020-0919-0","article-title":"The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy","volume":"55","author":"Ljungman","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40959-021-00113-y","article-title":"Impact of cancer and cardiovascular disease on in-hospital outcomes of COVID-19 patients: Results from the american heart association COVID-19 cardiovascular disease registry","volume":"7","author":"Tehrani","year":"2021","journal-title":"Cardio-Oncology"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1007\/s40615-021-01098-1","article-title":"Risk Factors for Death Among Hospitalized Patients Aged 21\u201364 Years Diagnosed with COVID-19\u2014New York City, March 13\u2013April 9, 2020","volume":"9","author":"Bushman","year":"2022","journal-title":"J. Racial Ethn. Health Disparities"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ijc.33846","article-title":"Cancer and the risk of coronavirus disease 2019 diagnosis, hospitalisation and death: A population-based multistate cohort study including 4 618 377 adults in Catalonia, Spain","volume":"150","author":"Roel","year":"2022","journal-title":"Int. J. Cancer"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1182\/blood.2021013768","article-title":"Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting","volume":"139","author":"Mittelman","year":"2022","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000522436","article-title":"COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments","volume":"145","author":"Sica","year":"2022","journal-title":"Acta Haematol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1158\/2159-8290.CD-21-1368","article-title":"Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer","volume":"12","author":"Elkrief","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11912-022-01198-z","article-title":"Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic","volume":"24","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2021.03.035","article-title":"Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: A European study","volume":"150","author":"Pinato","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1016\/j.clml.2021.06.024","article-title":"Frequency, Clinical Characteristics and Outcome of Adults with Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain","volume":"21","author":"Ribera","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejca.2021.08.007","article-title":"Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy\u2014A single center prospective study","volume":"157","author":"Shmueli","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cmi.2021.06.036","article-title":"BNT162b2 vaccine breakthrough: Clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel","volume":"27","author":"Chowers","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"100274","DOI":"10.1016\/j.esmoop.2021.100274","article-title":"Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment","volume":"6","author":"Peeters","year":"2021","journal-title":"ESMO Open"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/ajh.26209","article-title":"Prolonged in-hospital stay and higher mortality after COVID-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy","volume":"96","author":"Lamure","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s12029-021-00677-z","article-title":"Identifying the Risk Factors for Mortality in Patients with Cancer and COVID-19 in Hamadan, the West of Iran","volume":"53","author":"Safari","year":"2022","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1016\/S2352-3018(21)00070-9","article-title":"Overview of SARS-CoV-2 infection in adults living with HIV","volume":"8","author":"Ambrosioni","year":"2021","journal-title":"Lancet HIV"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1093\/cid\/ciaa579","article-title":"Clinical Features and Outcomes of Patients with Human Immunodeficiency Virus with COVID-19","volume":"71","author":"Gervasoni","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/QAI.0000000000002423","article-title":"Outcomes Among HIV-Positive Patients Hospitalized with COVID-19","volume":"85","author":"Carlucci","year":"2020","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e25573","DOI":"10.1002\/jia2.25573","article-title":"SARS-CoV-2 and HIV coinfection: Clinical experience from Rhode Island, United States","volume":"23","author":"Byrd","year":"2020","journal-title":"J. Int. AIDS Soc."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1097\/QAD.0000000000002643","article-title":"Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: A single-center, prospective observational study","volume":"34","author":"Inciarte","year":"2020","journal-title":"AIDS"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/hiv.12911","article-title":"Coronavirus disease 2019 (COVID-19) outcomes in HIV\/AIDS patients: A systematic review","volume":"21","author":"Cooper","year":"2020","journal-title":"HIV Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1093\/cid\/ciaa635","article-title":"Clinical Characteristics and Outcomes in People Living with Human Immunodeficiency Virus Hospitalized for Coronavirus Disease 2019","volume":"71","author":"Shalev","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1093\/cid\/ciaa880","article-title":"Coronavirus 2019 and People Living with Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City","volume":"71","author":"Sigel","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/QAI.0000000000002531","article-title":"COVID-19 Susceptibility and Outcomes Among People Living with HIV in San Francisco","volume":"86","author":"Sachdev","year":"2021","journal-title":"J. Acquir. Immune. Defic. Syndr."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cmi.2021.06.023","article-title":"Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort","volume":"27","author":"Berenguer","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jinf.2021.11.002","article-title":"Similar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19","volume":"84","author":"Berenguer","year":"2022","journal-title":"J. Infect."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.1016\/S2352-3018(20)30111-9","article-title":"COVID-19 in patients with HIV: Clinical case series","volume":"7","author":"Blanco","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_170","unstructured":"Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases (South Africa) (2021). Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. Clin Infect Dis., 73, e2005\u2013e2015."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0000000000002836","article-title":"Risk of adverse coronavirus disease 2019 outcomes for people living with HIV","volume":"35","author":"Mellor","year":"2021","journal-title":"AIDS"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"E1021","DOI":"10.1093\/cid\/ciaa1793","article-title":"Coronavirus Disease 2019 (COVID-19) Infection Among People with Human Immunodeficiency Virus in New York City: A Population-Level Analysis of Linked Surveillance Data","volume":"72","author":"Braunstein","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e1030","DOI":"10.1093\/cid\/ciaa1946","article-title":"When Epidemics Collide: Why People with Human Immunodeficiency Virus May Have Worse Coronavirus Disease 2019 Outcomes and Implications for Vaccination","volume":"72","author":"Triant","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1007\/s10461-022-03578-9","article-title":"Risk Factors for COVID-19 Mortality Among People Living with HIV: A Scoping Review","volume":"26","author":"Varshney","year":"2022","journal-title":"AIDS Behav."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/hiv.13167","article-title":"COVID-19 mortality among people with diagnosed HIV compared to those without during the first wave of the COVID-19 pandemic in England","volume":"23","author":"Brown","year":"2022","journal-title":"HIV Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.1016\/S2352-3018(20)30164-8","article-title":"Description of COVID-19 in HIV-infected individuals: A single-center, prospective cohort","volume":"7","author":"Vizcarra","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1097\/QAD.0000000000002607","article-title":"Disproportionate burden of coronavirus disease 2019 among racial minorities and those in congregate settings among a large cohort of people with HIV","volume":"34","author":"Meyerowitz","year":"2020","journal-title":"AIDS"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1097\/QAD.0000000000002663","article-title":"Factors associated with hospital admission for COVID-19 in HIV patients","volume":"34","author":"Ricci","year":"2020","journal-title":"AIDS"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1097\/QAD.0000000000002651","article-title":"HIV infection and COVID-19: Risk factors for severe disease","volume":"34","author":"Etienne","year":"2020","journal-title":"AIDS"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"F3","DOI":"10.1097\/QAD.0000000000002666","article-title":"Characteristics and outcomes of COVID-19 in patients with HIV: A multicentre research network study","volume":"34","author":"Hadi","year":"2020","journal-title":"AIDS"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10461-020-02983-2","article-title":"COVID-19 Among People Living with HIV: A Systematic Review","volume":"25","author":"Mirzaei","year":"2021","journal-title":"AIDS Behav."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3018(20)30305-2","article-title":"HIV infection and COVID-19 death: A population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform","volume":"8","author":"Bhaskaran","year":"2021","journal-title":"Lancet HIV"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"e2037069","DOI":"10.1001\/jamanetworkopen.2020.37069","article-title":"COVID-19 Outcomes Among Persons Living with or without Diagnosed HIV Infection in New York State","volume":"4","author":"Tesoriero","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/infdis\/jiaa380","article-title":"Clinical Outcomes and Immunologic Characteristics of Coronavirus Disease 2019 in People with Human Immunodeficiency Virus","volume":"223","author":"Ho","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_185","unstructured":"BHIVA DEGPSAS and PA for the Clinical Study of A (APECS) (2022, September 06). BHIVA, DAIG, EACS, GESIDA, Polish Scientific AIDS Society and Portuguese Association for the clinical study of AIDS (APECS). Available online: https:\/\/www.bhiva.org\/joint-statement-on-risk-of-COVID-19-for-PLWH-and-SARS-CoV-2-vaccine-advice."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/QAD.0000000000003132","article-title":"SARS-CoV-2 infection and coronavirus disease 2019 severity in persons with HIV on antiretroviral treatment","volume":"36","author":"Polo","year":"2022","journal-title":"AIDS"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/QAI.0000000000002989","article-title":"Factors Associated with Severity of COVID-19 Disease in a Multicenter Cohort of People with HIV in the United States, March\u2013December 2020","volume":"90","author":"Shapiro","year":"2022","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/cid\/ciaa657","article-title":"Hospitalized Patients with COVID-19 and Human Immunodeficiency Virus: A Case Series","volume":"71","author":"Childs","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/hiv.13145","article-title":"COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study","volume":"22","author":"Mican","year":"2021","journal-title":"HIV Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"e2236397","DOI":"10.1001\/jamanetworkopen.2022.36397","article-title":"Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults with and without HIV in the US","volume":"5","author":"Lang","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.1016\/S2352-3018(21)00151-X","article-title":"Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: A cohort study","volume":"8","author":"Jassat","year":"2021","journal-title":"Lancet HIV"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1016\/S2352-3018(21)00239-3","article-title":"Associations between HIV infection and clinical spectrum of COVID-19: A population level analysis based on US National COVID Cohort Collaborative (N3C) data","volume":"8","author":"Yang","year":"2021","journal-title":"Lancet HIV"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12981-021-00427-y","article-title":"Outcomes of patients with HIV and COVID-19 co-infection: A systematic review and meta-analysis","volume":"19","author":"Danwang","year":"2022","journal-title":"AIDS Res. Ther."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/hiv.13037","article-title":"Immune deficiency is a risk factor for severe COVID-19 in people living with HIV","volume":"22","author":"Hoffmann","year":"2021","journal-title":"HIV Med."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/QAI.0000000000002578","article-title":"Clinical Outcomes and Inflammatory Markers by HIV Serostatus and Viral Suppression in a Large Cohort of Patients Hospitalized with COVID-19","volume":"86","author":"Patel","year":"2021","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.coi.2019.03.008","article-title":"Human inborn errors of immunity to infection affecting cells other than leukocytes: From the immune system to the whole organism","volume":"59","author":"Zhang","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.coi.2019.12.002","article-title":"Recent human genetic errors of innate immunity leading to increased susceptibility to infection","volume":"62","author":"Moens","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00439-020-02127-5","article-title":"Herpes simplex virus encephalitis of childhood: Inborn errors of central nervous system cell-intrinsic immunity","volume":"139","author":"Zhang","year":"2020","journal-title":"Hum. Genet."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood.2019000928","article-title":"Primary immunodeficiencies reveal the molecular requirements for effective host defense against EBV infection","volume":"135","author":"Tangye","year":"2020","journal-title":"Blood"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00439-020-02137-3","article-title":"Genetic determinants of host immunity against human rhinovirus infections","volume":"139","author":"Lamborn","year":"2020","journal-title":"Hum. Genet."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"100018","DOI":"10.1016\/j.waojou.2019.100018","article-title":"X-linked agammaglobulinemia (XLA): Phenotype, diagnosis, and therapeutic challenges around the world","volume":"12","author":"Abramova","year":"2019","journal-title":"World Allergy Organ. J."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"614086","DOI":"10.3389\/fimmu.2020.614086","article-title":"Minor Clinical Impact of COVID-19 Pandemic on Patients with Primary Immunodeficiency in Israel","volume":"11","author":"Marcus","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jaci.2020.09.010","article-title":"Coronavirus disease 2019 in patients with inborn errors of immunity: An international study","volume":"147","author":"Meyts","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"994253","DOI":"10.3389\/fimmu.2022.994253","article-title":"Outcome of SARS-CoV-2 infection among patients with common variable immunodeficiency and a matched control group: A Danish nationwide cohort study","volume":"13","author":"Katzenstein","year":"2022","journal-title":"Front Immunol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/ACI.0000000000000786","article-title":"Mechanisms underlying host defense and disease pathology in response to severe acute respiratory syndrome (SARS)-CoV2 infection: Insights from inborn errors of immunity","volume":"21","author":"Tangye","year":"2021","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"2000547","DOI":"10.1183\/13993003.00547-2020","article-title":"Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis","volume":"55","author":"Guan","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"668808","DOI":"10.3389\/fmed.2021.668808","article-title":"The Risk of COVID-19 Related Hospitalsation, Intensive Care Unit Admission and Mortality in People with Underlying Asthma or COPD: A Systematic Review and Meta-Analysis","volume":"8","author":"Pardhan","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1164\/rccm.202006-2441LE","article-title":"Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A Case\u2013Control Study","volume":"202","author":"Esposito","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaci.2021.03.034","article-title":"Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis","volume":"148","author":"Lemarquis","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"e20210554","DOI":"10.1084\/jem.20210554","article-title":"Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1","volume":"218","author":"Bastard","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"e150867","DOI":"10.1172\/JCI150867","article-title":"Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1","volume":"131","author":"Meisel","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"eabl4340","DOI":"10.1126\/sciimmunol.abl4340","article-title":"Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths","volume":"6","author":"Heim","year":"2021","journal-title":"Sci. Immunol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","article-title":"Auto-antibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"e2200413119","DOI":"10.1073\/pnas.2200413119","article-title":"The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies","volume":"119","author":"Manry","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/jama.2020.13719","article-title":"Presence of Genetic Variants Among Young Men with Severe COVID-19","volume":"324","author":"Simons","year":"2020","journal-title":"JAMA"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"eabl4348","DOI":"10.1126\/sciimmunol.abl4348","article-title":"X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19","volume":"6","author":"Asano","year":"2021","journal-title":"Sci. Immunol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"25018","DOI":"10.1073\/pnas.2010540117","article-title":"Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients","volume":"117","author":"Holter","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_218","first-page":"50","article-title":"Implications of SARSr-CoV 2 infection in thalassemias: Do patients fall into the \u201chigh clinical risk\u201d category?","volume":"91","author":"Karimi","year":"2020","journal-title":"Acta Biomed."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/s41591-020-1021-2","article-title":"Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection","volume":"26","author":"Ramlall","year":"2020","journal-title":"Nat. Med."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jaip.2020.11.042","article-title":"COVID-19 affecting hereditary angioedema patients with and without C1 inhibitor deficiency","volume":"9","author":"Grumach","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s10875-021-01066-8","article-title":"Outcome of SARS-CoV-2 Infection in 121 Patients with Inborn Errors of Immunity: A Cross-Sectional Study","volume":"41","author":"Goudouris","year":"2021","journal-title":"J. Clin. Immunol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1136\/annrheumdis-2020-218296","article-title":"Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: A multicentric matched cohort study","volume":"79","author":"Pablos","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3899\/jrheum.200755","article-title":"Risk of Severe COVID-19 Infection in Patients with Inflammatory Rheumatic Diseases","volume":"48","author":"Boteanu","year":"2021","journal-title":"J. Rheumatol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/annrheumdis-2020-219564","article-title":"Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: A nationwide study from Iceland","volume":"80","author":"Bjornsson","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/annrheumdis-2021-219845","article-title":"Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: A nationwide Swedish cohort study","volume":"80","author":"Bower","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"SI59","DOI":"10.1093\/rheumatology\/keaa897","article-title":"Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: A nationwide cohort study from Denmark","volume":"60","author":"Cordtz","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/art.42030","article-title":"SARS\u2013CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis","volume":"74","author":"Conway","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s42399-020-00363-4","article-title":"Comorbidity and its Impact on Patients with COVID-19","volume":"2","author":"Sanyaolu","year":"2020","journal-title":"SN Compr. Clin. Med."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1016\/S2665-9913(20)30169-7","article-title":"COVID-19 in patients with rheumatic diseases in northern Italy: A single-center observational and case\u2013control study","volume":"2","author":"Fredi","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"102597","DOI":"10.1016\/j.autrev.2020.102597","article-title":"COVID-19 and autoimmunity","volume":"19","author":"Ehrenfeld","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"102575","DOI":"10.1016\/j.autrev.2020.102575","article-title":"SARS-CoV-2 infection among patients with systemic autoimmune diseases","volume":"19","author":"Emmi","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"S737","DOI":"10.1136\/annrheumdis-2020-217460","article-title":"Role of immunosuppressive therapy in rheumatic diseases concurrent with COVID-19","volume":"79","author":"Lu","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"e490","DOI":"10.1016\/S2665-9913(22)00098-4","article-title":"Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: A nationwide cohort study in the OpenSAFELY platform","volume":"4","author":"MacKenna","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1136\/annrheumdis-2020-218152","article-title":"Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors","volume":"81","author":"Jovani","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.semarthrit.2020.06.012","article-title":"COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients","volume":"50","author":"Ramirez","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/annrheumdis-2020-217903","article-title":"Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: A population-based study","volume":"79","author":"Salvarani","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"FAI2R \/SFR\/SNFMI\/SOFREMIP\/CRI\/IMIDIATE Consortium and Contributors (2021). Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: Data from the French RMD COVID-19 cohort of 694 patients. Ann. Rheum. Dis., 80, 527\u2013538.","DOI":"10.1136\/annrheumdis-2020-218310"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"103104","DOI":"10.1016\/j.msard.2021.103104","article-title":"Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia","volume":"54","author":"Stastna","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"7591141","DOI":"10.1155\/2021\/7591141","article-title":"Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease","volume":"2021","author":"Wetwittayakhlang","year":"2021","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2020.05.032","article-title":"Corticosteroids, But Not TNF Antagonists, Are Associated with Adverse COVID-19 Outcomes in Patients with Inflammatory Bowel Diseases: Results from an International Registry","volume":"159","author":"Brenner","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"80","author":"Strangfeld","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"e001464","DOI":"10.1136\/rmdopen-2020-001464","article-title":"Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases","volume":"7","author":"Hasseli","year":"2021","journal-title":"RMD Open"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"102613","DOI":"10.1016\/j.jaut.2021.102613","article-title":"Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies\u2014A Danish population-based cohort study","volume":"118","author":"Attauabi","year":"2021","journal-title":"J. Autoimmun."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S2213-2600(21)00543-9","article-title":"Risk of serious COVID-19 outcomes among adults with asthma in Scotland: A national incident cohort study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/annrheumdis-2021-220604","article-title":"Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases","volume":"80","author":"Spiera","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/annrheumdis-2021-220656","article-title":"High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases","volume":"80","author":"Ruddy","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.semarthrit.2021.08.010","article-title":"Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States","volume":"51","author":"Raiker","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/S2665-9913(21)00325-8","article-title":"Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: A retrospective cohort study using data from the National COVID Cohort Collaborative","volume":"4","author":"Andersen","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"ref_250","doi-asserted-by":"crossref","unstructured":"Garcill\u00e1n, B., Salavert, M., Regueiro, J.R., and D\u00edaz-Castroverde, S. (2022). Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review. Vaccines, 10.","DOI":"10.3390\/vaccines10020297"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/rheumatology\/keac422","article-title":"Different COVID-19 outcomes among systemic rheumatic diseases: A nation-wide cohort study","volume":"62","author":"Bournia","year":"2023","journal-title":"Rheumatology (Oxford)"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/7\/1449\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:01:55Z","timestamp":1760126515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/7\/1449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":251,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["v15071449"],"URL":"https:\/\/doi.org\/10.3390\/v15071449","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2023,6,27]]}}}